In a report issued on May 17, Mani Foroohar from SVB Securities maintained a Sell rating on Moderna (MRNA – Research Report). The company's shares closed last Wednesday at $137.71, close to its 52-week low of $119.01. According to TipRanks.com, Foroohar 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -21.9% and a 34.7% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics. Currently, the analyst consensus on Moderna is a Moderate Buy with an average price target of $254.67.
https://www.tipranks.com/news/blurbs/svb-securities-maintains-a-sell-rating-on-moderna-mrna?utm_source=advfn.com&utm_medium=referral